An observational trial to evaluate the influence of CYP3A4*1G allele on the pharmacokinetics and pharmacodynamics of clopidogrel

Trial Profile

An observational trial to evaluate the influence of CYP3A4*1G allele on the pharmacokinetics and pharmacodynamics of clopidogrel

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Coronary disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 27 Feb 2016 New trial record
    • 18 Feb 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top